Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/39075
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shah, Amil. M. M. | - |
dc.contributor.author | Claggett, Brian | - |
dc.contributor.author | Prasad, Narayana | - |
dc.contributor.author | Li, Guichu | - |
dc.contributor.author | Volquez, Mayra | - |
dc.contributor.author | Jering, Karola | - |
dc.contributor.author | Cikes, Maja | - |
dc.contributor.author | Kovacs, Attila | - |
dc.contributor.author | MULLENS, Wilfried | - |
dc.contributor.author | Nicolau, Jose C. | - |
dc.contributor.author | Kober, Lars | - |
dc.contributor.author | Van der Meer, Peter | - |
dc.contributor.author | Jhund, Pardeep. S. S. | - |
dc.contributor.author | Ibram, Ghionul | - |
dc.contributor.author | Lefkowitz, Martin | - |
dc.contributor.author | Zhou , Yinong | - |
dc.contributor.author | Solomon, Scott. D. D. | - |
dc.contributor.author | Pfeffer, Marc A. | - |
dc.date.accessioned | 2022-12-19T10:02:07Z | - |
dc.date.available | 2022-12-19T10:02:07Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2022-12-09T13:42:46Z | - |
dc.identifier.citation | CIRCULATION, 146 (14) , p. 1067 -1081 | - |
dc.identifier.uri | http://hdl.handle.net/1942/39075 | - |
dc.description.abstract | BACKGROUND: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV) enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits with combined angiotensin receptor neprilysin inhibition, but human data are conflicting. The PARADISE-MI Echo Study (Prospective ARNI Versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction) tested the effect of sacubitril/valsartan compared with ramipril on LV function and adverse remodeling after high risk-AMI. METHODS: In a prespecified substudy, 544 PARADISE-MI participants were enrolled in the Echo Study to undergo protocol echocardiography at randomization and after 8 months. Patients were randomized within 0.5 to 7 days of presentation with their index AMI to receive a target dose of sacubitril/valsartan 200 mg or ramipril 5 mg twice daily. Echocardiographic measures were performed at a core laboratory by investigators blinded to treatment assignment. The effect of treatment on change in echo measures was assessed with ANCOVA with adjustment for baseline value and enrollment region. The primary end points were change in LV ejection fraction (LVEF) and left atrial volume (LAV), and prespecified secondary end points included changes in LV end-diastolic and end-systolic volumes. RESULTS: Mean age was 64 & PLUSMN;12 years; 26% were women; mean LVEF was 42 & PLUSMN;12%; and LAV was 49 & PLUSMN;17 mL. Of 544 enrolled patients, 457 (84%) had a follow-up echo at 8 months (228 taking sacubitril/valsartan, 229 taking ramipril). There was no significant difference in change in LVEF (P=0.79) or LAV (P =0.62) by treatment group. Patients randomized to sacubitril/valsartan demonstrated less increase in LV end-diastolic volume (P=0.025) and greater decline in LV mass index (P=0.037), increase in tissue Doppler e'(lat) (P=0.005), decrease in E/e'(lat) (P=0.045), and decrease in tricuspid regurgitation peak velocity (P=0.024) than patients randomized to ramipril. These differences remained significant after adjustment for differences in baseline characteristics. Baseline LVEF, LV end-diastolic volume, LV end-systolic volume, LV mass index, LAV, and Doppler-based diastolic indices were associated with risk of cardiovascular death or incident heart failure. CONSLUSIONS: Treatment with sacubitril/valsartan compared with ramipril after AMI did not result in changes in LVEF or LAV at 8 months. Patients randomized to sacubitril/valsartan had less LV enlargement and greater improvement in filling pressure. Measures of LV size, systolic function, and diastolic properties were predictive of cardiovascular death and incident heart failure after AMI in this contemporary, well-treated cohort. | - |
dc.description.sponsorship | The PARADISE-MI trial was funded by Novartis. Dr Shah was also supported by National Institutes of Health/National Heart, Lung, and Blood Institute grants R01HL135008, R01HL143224, R01HL150342, R01HL148218, R01HL160025, and K24HL152008. Dr Nicolau is recipient of a scholarship from Conselho Nacional de Pesquisa e Desenvolvimento Tecnológico (National Council for Scientific and Technological Development), Brazil (CNPq No. 301242/2017-8). | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.rights | 2022 American Heart Association, Inc | - |
dc.subject.other | echocardiography | - |
dc.subject.other | heart failure | - |
dc.subject.other | myocardial infarction | - |
dc.title | Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1081 | - |
dc.identifier.issue | 14 | - |
dc.identifier.spage | 1067 | - |
dc.identifier.volume | 146 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Shah, AM (corresponding author), Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boson 02445, MA USA. | - |
dc.description.notes | BCLAGGETT@BWH.HARVARD.EDU; nprasad@bwh.harvard.edu; | - |
dc.description.notes | gli14@bwh.harvard.edu; MVOLQUEZ@BWH.HARVARD.EDU; | - |
dc.description.notes | kjering@bwh.harvard.edu; maja.cikes@gmail.com; | - |
dc.description.notes | attila.kovacs@med.semmelweis-univ.hu; wilfried.mullens@gmail.com; | - |
dc.description.notes | corjnicolau@incor.usp.br; Lars.koeber.01@regionh.dk; | - |
dc.description.notes | p.van.der.meer@umcg.nl; pardeep.jhund@glasgow.ac.uk; | - |
dc.description.notes | ghionul.ibram@novartis.com; marty.lefkowitz@novartis.com; | - |
dc.description.notes | yinong.zhou@novartis.com; ssolomon@bwh.harvard.edu; | - |
dc.description.notes | mpfeffer@rics.bwh.harvard.edu | - |
local.publisher.place | TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1161/CIRCULATIONAHA.122.059210 | - |
dc.identifier.pmid | 36082663 | - |
dc.identifier.isi | 000886562300005 | - |
dc.contributor.orcid | Jering, Karola/0000-0002-5243-1959; Kovacs, Attila/0000-0003-2320-6434 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Shah, Amil. M. M.; Claggett, Brian; Prasad, Narayana; Li, Guichu; Volquez, Mayra; Jering, Karola; Solomon, Scott. D. D.; Pfeffer, Marc A.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA. | - |
local.description.affiliation | [Cikes, Maja] Univ Zagreb Sch Med, Zagreb, Croatia. | - |
local.description.affiliation | [Cikes, Maja] Univ Hosp Ctr Zagreb, Zagreb, Croatia. | - |
local.description.affiliation | [Kovacs, Attila] Semmelwe Univ, Heart & Vasc Ctr, Budapest, Hungary. | - |
local.description.affiliation | [Mullens, Wilfried] Univ Hasselt, Ziekenhuis Oost Limburg, Genk, Belgium. | - |
local.description.affiliation | [Nicolau, Jose C.] Univ Sao Paulo, Hosp Clin, Fac Med, Inst Coracao, Sao Paulo, Brazil. | - |
local.description.affiliation | [Kober, Lars] Rigshospitalet, Copenhagen, Denmark. | - |
local.description.affiliation | Univ Groningen, Groningen, Netherlands. | - |
local.description.affiliation | [Jhund, Pardeep. S. S.] Univ Glasgow, Glasgow, Scotland. | - |
local.description.affiliation | [Ibram, Ghionul; Lefkowitz, Martin; Zhou, Yinong] Novartis Pharmaceut, E Hanover, NJ USA. | - |
local.description.affiliation | [Shah, Amil. M. M.] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boson 02445, MA USA. | - |
local.uhasselt.international | yes | - |
item.contributor | Shah, Amil. M. M. | - |
item.contributor | Claggett, Brian | - |
item.contributor | Prasad, Narayana | - |
item.contributor | Li, Guichu | - |
item.contributor | Volquez, Mayra | - |
item.contributor | Jering, Karola | - |
item.contributor | Cikes, Maja | - |
item.contributor | Kovacs, Attila | - |
item.contributor | MULLENS, Wilfried | - |
item.contributor | Nicolau, Jose C. | - |
item.contributor | Kober, Lars | - |
item.contributor | Van der Meer, Peter | - |
item.contributor | Jhund, Pardeep. S. S. | - |
item.contributor | Ibram, Ghionul | - |
item.contributor | Lefkowitz, Martin | - |
item.contributor | Zhou , Yinong | - |
item.contributor | Solomon, Scott. D. D. | - |
item.contributor | Pfeffer, Marc A. | - |
item.fulltext | With Fulltext | - |
item.validation | ecoom 2023 | - |
item.fullcitation | Shah, Amil. M. M.; Claggett, Brian; Prasad, Narayana; Li, Guichu; Volquez, Mayra; Jering, Karola; Cikes, Maja; Kovacs, Attila; MULLENS, Wilfried; Nicolau, Jose C.; Kober, Lars; Van der Meer, Peter; Jhund, Pardeep. S. S.; Ibram, Ghionul; Lefkowitz, Martin; Zhou , Yinong; Solomon, Scott. D. D. & Pfeffer, Marc A. (2022) Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. In: CIRCULATION, 146 (14) , p. 1067 -1081. | - |
item.accessRights | Open Access | - |
crisitem.journal.issn | 0009-7322 | - |
crisitem.journal.eissn | 1524-4539 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
00003017-202210040-00004.pdf | Published version | 1.16 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.